Cargando…
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
Mucositis is a highly significant, and sometimes dose‐limiting, toxicity of cancer therapy. This article presents evidence‐based clinical practice guidelines for the management of mucositis.
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Wiley
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164022/ https://www.ncbi.nlm.nih.gov/pubmed/24615748 http://dx.doi.org/10.1002/cncr.28592 |
| _version_ | 1782334901105721344 |
|---|---|
| author | Lalla, Rajesh V. Bowen, Joanne Barasch, Andrei Elting, Linda Epstein, Joel Keefe, Dorothy M. McGuire, Deborah B. Migliorati, Cesar Nicolatou‐Galitis, Ourania Peterson, Douglas E. Raber‐Durlacher, Judith E. Sonis, Stephen T. Elad, Sharon |
| author_facet | Lalla, Rajesh V. Bowen, Joanne Barasch, Andrei Elting, Linda Epstein, Joel Keefe, Dorothy M. McGuire, Deborah B. Migliorati, Cesar Nicolatou‐Galitis, Ourania Peterson, Douglas E. Raber‐Durlacher, Judith E. Sonis, Stephen T. Elad, Sharon |
| author_sort | Lalla, Rajesh V. |
| collection | PubMed |
| description | Mucositis is a highly significant, and sometimes dose‐limiting, toxicity of cancer therapy. This article presents evidence‐based clinical practice guidelines for the management of mucositis. |
| format | Online Article Text |
| id | pubmed-4164022 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2014 |
| publisher | Wiley |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-41640222014-09-22 MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy Lalla, Rajesh V. Bowen, Joanne Barasch, Andrei Elting, Linda Epstein, Joel Keefe, Dorothy M. McGuire, Deborah B. Migliorati, Cesar Nicolatou‐Galitis, Ourania Peterson, Douglas E. Raber‐Durlacher, Judith E. Sonis, Stephen T. Elad, Sharon Cancer Review Articles Mucositis is a highly significant, and sometimes dose‐limiting, toxicity of cancer therapy. This article presents evidence‐based clinical practice guidelines for the management of mucositis. Wiley 2014-02-25 2014-05-06 /pmc/articles/PMC4164022/ /pubmed/24615748 http://dx.doi.org/10.1002/cncr.28592 Text en © 2014 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/3.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| spellingShingle | Review Articles Lalla, Rajesh V. Bowen, Joanne Barasch, Andrei Elting, Linda Epstein, Joel Keefe, Dorothy M. McGuire, Deborah B. Migliorati, Cesar Nicolatou‐Galitis, Ourania Peterson, Douglas E. Raber‐Durlacher, Judith E. Sonis, Stephen T. Elad, Sharon MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy |
| title | MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy |
| title_full | MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy |
| title_fullStr | MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy |
| title_full_unstemmed | MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy |
| title_short | MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy |
| title_sort | mascc/isoo clinical practice guidelines for the management of mucositis secondary to cancer therapy |
| topic | Review Articles |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164022/ https://www.ncbi.nlm.nih.gov/pubmed/24615748 http://dx.doi.org/10.1002/cncr.28592 |
| work_keys_str_mv | AT lallarajeshv masccisooclinicalpracticeguidelinesforthemanagementofmucositissecondarytocancertherapy AT bowenjoanne masccisooclinicalpracticeguidelinesforthemanagementofmucositissecondarytocancertherapy AT baraschandrei masccisooclinicalpracticeguidelinesforthemanagementofmucositissecondarytocancertherapy AT eltinglinda masccisooclinicalpracticeguidelinesforthemanagementofmucositissecondarytocancertherapy AT epsteinjoel masccisooclinicalpracticeguidelinesforthemanagementofmucositissecondarytocancertherapy AT keefedorothym masccisooclinicalpracticeguidelinesforthemanagementofmucositissecondarytocancertherapy AT mcguiredeborahb masccisooclinicalpracticeguidelinesforthemanagementofmucositissecondarytocancertherapy AT miglioraticesar masccisooclinicalpracticeguidelinesforthemanagementofmucositissecondarytocancertherapy AT nicolatougalitisourania masccisooclinicalpracticeguidelinesforthemanagementofmucositissecondarytocancertherapy AT petersondouglase masccisooclinicalpracticeguidelinesforthemanagementofmucositissecondarytocancertherapy AT raberdurlacherjudithe masccisooclinicalpracticeguidelinesforthemanagementofmucositissecondarytocancertherapy AT sonisstephent masccisooclinicalpracticeguidelinesforthemanagementofmucositissecondarytocancertherapy AT eladsharon masccisooclinicalpracticeguidelinesforthemanagementofmucositissecondarytocancertherapy AT masccisooclinicalpracticeguidelinesforthemanagementofmucositissecondarytocancertherapy |